1-3 of 3
Joachim Stangier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

Joanne van Ryn, PhD, Masahiro Yasaka, MD PhD, Ippei Ikushima, MD PhD, Akiko Harada, PhD, Atsushi Taniguchi, MSc, Susumu Imazu, PhD, Stephen Norris, PhD, Dietmar Gansser, PhD, Joachim Stangier, PhD
Journal: Blood
Blood (2016) 128 (22): 2627.
https://doi.org/10.1182/blood.V128.22.2627.2627
Published: 2016
Journal Articles

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

Stephan Glund, Joachim Stangier, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Gansser, Stephen Norris, Benjamin Lang, Paul Reilly, MD
Journal: Blood
Blood (2014) 124 (21): 344.
https://doi.org/10.1182/blood.V124.21.344.344
Published: 2014
Journal Articles

Validation of the HEMOCLOT ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery

Joachim Stangier, PhD, Bengt I Eriksson, MD, Michael H Huo, MD, Richard J Friedman, MD, Ola E Dahl, MD, Martin Feuring, MD
Journal: Blood
Blood (2011) 118 (21): 2307.
https://doi.org/10.1182/blood.V118.21.2307.2307
Published: 2011